Ranbaxy at back foot: Punjab’s plant (4th in India) banned by FDA

Ranbaxy Laboratories which is one of the largest and reputed companies of India, exports its drugs throughout the world. U.S. is the main consumer of generic drugs made at Ranbaxy but due to one defect found in the drugs of Toansa plant in Punjab, Ranbaxy got a setback on their reputation. This is the fourth plant of India which was banned by U.S. Food …

Efavirenz (HIV Drug) case: Bristol (BMS) won over Mylan Pharma

Bristol Meyers Squibb (BMS), manufacturers of Efavirenz (patented drug for HIV) won over the companies named Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd. that made generic version of Efavirenz that is Sustiva. The companies filed an application in court for the permission to manufacture and sell Sustiva before the patent granted for Efavirenz …

Pharmaceutical Companies shift from Small Molecule Drugs to Biotech Drugs

Recently, the Tufts University’s Center for the Study of Drug Development (CSDD) released an interesting report revealing the dramatic shift of pharmaceutical companies from manufacturing small molecule drugs to a large number of biotechnology drugs. The report shows that in 2001, the biotech products worldwide accounted for only 7% of the revenue …

ViaCyte: Regenerative Medicine and Cell Therapy Derived from Stem Cells

ViaCyte Inc. is emerging as a leader in regenerative medicine and is all set to develop a new approach for the treatment of major diseases using cell therapy derived from stem cells. The company was granted 28 patents in 2011-2013 of which 17 are US and remaining 11 in other countries. Among the 11 patents, one of the patents got granted in Europe patent …

Important Drug Patents to Expire in 2014 for Generic Production

Year 2014 would be a big loss year for the Pharma companies because of the expiry of patents granted for some of the major medicines. It is estimated that due to the loss of IP protection, sales worth $34 billion is under danger which is very high compared to $28 billion loss faced this year that is in 2013, though the loss would appear less when compared …

Unaffordable Life Saving Drug (Linezolid by Pfizer) Leaves TB Patients Struggling in South Africa

South Africa could not keep up with the treatment for Drug resistant Tuberculosis (TB), which has affected thousands of people in the country. Many of the sufferers would die and the death would be horrible and slow. Not only this, survivors would be struggling with many side effects like loss of hearing and would be requiring pills and injections daily. …

‘Fire In the Blood’ – An Eye Opener for Patent Law Makers in Pharmaceuticals

Fire in the Blood, is a documentary on “medicine, monopoly and malice.” It tells the story of how Western pharmaceutical companies and governments blocked access to low-cost AIDS drugs for the countries of the global south in the years after 1996 – causing ten million or more unnecessary deaths – and the improbable group of people …

Patent on Method of Cellular Differentiation Granted to Cellular Dynamics International (CDI)

CDI (Cellular Dynamics International), a leader in developing induced pluripotent stem cell technologies for in vitro drug development, in vivo cellular therapeutic research and stem cell banking was granted patent no. US8557580 on October 15, 2013 entitled “Methods and Compositions for the Differentiation of Stem Cells” by USPTO. The patent …